Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-743921 SCHEMBL29377772 | 1.00 | KIF11 (1.00) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL645543 | 1.00 | KIF11 (1.00) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL649759 | 0.99 | KIF11 (0.98) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL16354067 | 0.99 | KIF11 (0.98) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL644065 | 0.99 | KIF11 (0.98) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL644223 | 0.98 | KIF11 (0.97) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL362802 | 0.98 | KIF11 (0.97) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL645244 | 0.94 | KIF11 (0.88) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4262841 | 0.93 | KIF11 (0.87) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4262843 | 0.93 | KIF11 (0.87) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2023-10-19 | — | — | US | disclosed |
| US-11746354-B2 | Homology dependent repair genome editing | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023083900-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2023-05-19 | — | — | WO | disclosed |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2022-12-29 | — | — | US | disclosed |
| US-20220170034-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | INARI AGRICULTURE TECHNOLOGY, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2021048419-A1 | COMBINATION THERAPIES COMPRISING TRAMETINIB FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021048418-A1 | COMBINATION THERAPIES COMPRISING BORTEZOMIB FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021048417-A1 | COMBINATION THERAPIES COMPRISING DASATINIB FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2021-03-18 | — | — | WO | disclosed |
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHONGQING UPGRA BIOLOGICAL SCI. & TECH., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1511734-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1511734-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | KIF11 525/4885KCNH2 3954/4885MAP1LC3B 1728/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAP1LC3B 1516/4885 |
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | CALCR, BCR, PTH1R | KIF11 4530/4885KCNH2 3775/4885MAP1LC3B 3590/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAP1LC3B 1516/4885 |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | HDAC6, HDAC3, CHKA | KIF11 743/4885KCNH2 2608/4885MAP1LC3B 1101/4885 |
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, SLC11A2 | KIF11 129/4885KCNH2 4356/4885MAP1LC3B 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.